BRCA1 and prostate carcinoma: As the first FDA-approved anti-cancer drug that exploits the concept of synthetic lethality, PARP inhibitors (PARPi) are widely employed to treat breast, ovarian, pancreatic, and prostate cancer patients associated with BRCA1 and BRCA2 mutations [8].